GXEA Stock Overview
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Galapagos NV Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €26.20 |
52 Week High | €39.20 |
52 Week Low | €25.80 |
Beta | 0.021 |
1 Month Change | -9.66% |
3 Month Change | -22.02% |
1 Year Change | -21.56% |
3 Year Change | -60.90% |
5 Year Change | -73.80% |
Change since IPO | -40.54% |
Recent News & Updates
Recent updates
Shareholder Returns
GXEA | DE Biotechs | DE Market | |
---|---|---|---|
7D | -0.8% | -3.1% | 1.8% |
1Y | -21.6% | -22.4% | 2.2% |
Return vs Industry: GXEA matched the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: GXEA underperformed the German Market which returned 2.2% over the past year.
Price Volatility
GXEA volatility | |
---|---|
GXEA Average Weekly Movement | 5.5% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GXEA's share price has been volatile over the past 3 months.
Volatility Over Time: GXEA's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 1,123 | Paul Stoffels | www.glpg.com |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Galapagos NV Fundamentals Summary
GXEA fundamental statistics | |
---|---|
Market cap | €1.79b |
Earnings (TTM) | -€3.99m |
Revenue (TTM) | €239.72m |
7.5x
P/S Ratio-448.1x
P/E RatioIs GXEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GXEA income statement (TTM) | |
---|---|
Revenue | €239.72m |
Cost of Revenue | €241.29m |
Gross Profit | -€1.57m |
Other Expenses | €2.42m |
Earnings | -€3.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | -0.061 |
Gross Margin | -0.65% |
Net Profit Margin | -1.66% |
Debt/Equity Ratio | 0% |
How did GXEA perform over the long term?
See historical performance and comparison